Literature DB >> 2327748

Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis.

J Fierer1, T Kirkland, F Finley.   

Abstract

We infected mice with arthroconidia of Coccidioides immitis by intraperitoneal injection and 48 h later treated them with either oral fluconazole or SDZ89-485, a new triazole. Both drugs completely inhibited fungal growth when administered at a dose of 50 mg/kg of body weight twice a day, but only SDZ89-485 was fully inhibitory at a dose of 5 mg/kg twice a day. In a second experiment, treatment with SDZ89-485 was delayed until 8 days after infection to allow infection to be well established before treatment. Both 5 and 50 mg/kg twice a day were effective regimens, which establishes that SDZ89-485 has activity against spherules in vivo. Mice that received fluconazole (50 mg/kg twice a day) had a peak level in blood of 60 micrograms/ml 1 h after a dose, but no measurable amount was found after 12 h. SDZ89-485 was more slowly absorbed, reaching a peak level in blood of 14 micrograms/ml at 12 to 15 h after a dose of 50 mg/kg. We conclude that SDZ89-485 is more effective than fluconazole as treatment for experimental systemic coccidioidomycosis in mice, even though fluconazole achieves higher peak levels in blood.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327748      PMCID: PMC171511          DOI: 10.1128/AAC.34.1.13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice.

Authors:  C A Lyman; A M Sugar; R D Diamond
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

Review 3.  Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis.

Authors:  M S Brown; J L Goldstein
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

4.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

5.  Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858).

Authors:  J R Graybill; S H Sun; J Ahrens
Journal:  J Med Vet Mycol       Date:  1986-04

6.  Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

Authors:  W E Dismukes; A M Stamm; J R Graybill; P C Craven; D A Stevens; R L Stiller; G A Sarosi; G Medoff; C R Gregg; H A Gallis; B T Fields; R L Marier; T A Kerkering; L G Kaplowitz; G Cloud; C Bowles; S Shadomy
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

7.  Inbred mouse strains differ in resistance to lethal Coccidioides immitis infection.

Authors:  T N Kirkland; J Fierer
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

8.  Cyclosporin A inhibits Coccidioides immitis in vitro and in vivo.

Authors:  T N Kirkland; J Fierer
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

9.  Efficacies of four antifungal agents in experimental murine sporotrichosis.

Authors:  V L Kan; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

10.  Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.

Authors:  D S Loose; P B Kan; M A Hirst; R A Marcus; D Feldman
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

View more
  5 in total

Review 1.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

Review 2.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

3.  In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.

Authors:  T Tanio; K Ichise; T Nakajima; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 4.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

5.  APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia.

Authors:  Suganya Viriyakosol; Mili Kapoor; Sharon Okamoto; Jonathan Covel; Quinlyn A Soltow; Michael Trzoss; Karen Joy Shaw; Joshua Fierer
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.